McCullough Robertson has advised Prescient Therapeutics Limited (ASX: PTX) on the successful completion of its Share Purchase Plan (SPP), raising a total of $6.5 million.

The SPP received overwhelming support and was heavily oversubscribed.  The Melbourne-based biotechnology company is focused on the development of novel, personalised therapies against a range of cancers.  It will use the funds raised to progress its pipeline of cancer treatments, including clinical trials of PTX 100 and 200 products, and its cutting edge programs in cell therapy including the new OmniCAR platform for next-generation CAR-T therapies.

Lead Partner, Ben Wood comments ‘the completion of Prescient Therapeutics Limited’s SPP provides a great opportunity for ground breaking advancements in cancer treatments. We look forward to seeing the developments that will be made as a result’.

To read Prescient Therapeutics announcement, please click here.